

Zydus Cadila's Net Profit soars to Rs. 1151 crore

Ahmedabad, May 15, 2015

Announcing the results for the year ended 31st March 2015, Zydus Cadila registered a Net Profit of Rs. 1151 crores, up by 43% from Rs. 804 crores. During the year, the company registered gross sales of Rs. 8658 crores, up by 20% from Rs. 7208 crores in the corresponding period last year, on a consolidated basis.

For the fourth quarter ended 31st March 2015, the group registered gross sales of Rs. 2297 crores, up by 18% from Rs. 1952 crores in the corresponding period last year on a consolidated basis. Net Profit for the same period stood at Rs. 350 crores. The Board of Directors of the Company in their meeting proposed a dividend of 240%.

During the year, the group launched Exemptia, the world's first biosimilar for Adalimumab which is the largest selling therapy worldwide. This biosimilar is a part of the group's robust biologics programme which has the largest number of monoclonal antibodies under development in India. Exemptia is marketed by Zydus Biovation and Zydus BioNext - new divisions launched exclusively to market this ground breaking therapy for inflammatory arthritis and Inflammatory Bowel Disease. During the year, the group also launched SoviHep, the breakthrough therapy for Hepatitis C in alliance with Gilead Sciences.

Advancing its discovery research programme, the group has been exploring newer treatment options for its breakthrough drug Lipaglyn™ (Saroglitazar) and initiated Phase III trials of the molecule for patients suffering from lipodystrophy and nonalcoholic steatohepatitis (NASH), during the year. The group initiated Phase I clinical trials in the United States for ZYDPLA1, a novel, orally active, small molecule DPP-4 inhibitor to treat Type-2 Diabetes. Phase I clinical trials are also underway in Australia for its IND - ZYAN 1, a HIF-PH inhibitor for treating anemia.

Strengthening its regulatory pipeline, the group filed 38 ANDAs during the year with the US FDA, taking the cumulative filings to 260. The group received 8 ANDA approvals during the year taking the total to 99 product approvals.
